Vascularized Tissue-Engineered Model for Studying Drug Resistance in Neuroblastoma
Theranostics2017Vol. 7(17), pp. 4099–4117
Citations Over TimeTop 22% of 2017 papers
Aránzazu Villasante, K Sakaguchi, J. Kim, Nai‐Kong V. Cheung, Masamichi Nakayama, Hesam Parsa, Teruo Okano, Tatsuya Shimizu, Gordana Vunjak‐Novakovic
Abstract
Our results reveal some roles of SOX2 in drug resistance and tumor relapse, and suggest that SOX2 could be a therapeutic target in neuroblastoma.
Related Papers
- → Cancer Stem Cells in Glioblastoma Multiforme(2016)75 cited
- → Association of High Expression Levels of SOX2, NANOG, and OCT4 in Gastric Cancer Tumor Tissues with Progression and Poor Prognosis(2019)72 cited
- → The HPV16 E7 oncoprotein increases the expression of Oct3/4 and stemness-related genes and augments cell self-renewal(2016)32 cited
- → NANOG overexpression and its correlation with stem cell and differentiation markers in meningiomas of different WHO grades(2017)32 cited
- → Structural characterization of stem cell factors Oct4, Sox2, Nanog and Esrrb disordered domains, and a method to identify their phospho-dependent binding partners(2023)2 cited